What Sinofin treats: Main Uses and Benefits

Sinofin is an oral antifungal medication that is commonly used to help manage persistent and significant fungal infections affecting the nails, skin, and scalp. It is generally applied in contexts where infections may be deep-seated or widespread, often when topical treatments are not considered appropriate.

It is relevant in clinical settings that involve acute or unstable symptom patterns associated with the dermatophyte family of fungi. Specifically, the medicine is commonly used to help with fungal infections of the fingernails and toenails (onychomycosis), widespread tinea infections of the body and groin, and fungal infections of the scalp (Tinea capitis). This supports the patient's goal of achieving long-term resolution.

---

Quick Fact: Relief for Persistent Fungal Symptoms

Sinofin is applied in clinical settings that involve acute or unstable symptom patterns, which may help ease challenging manifestations that interfere with daily functioning. The overall therapeutic benefit is focused on supportive management and reducing the overall symptom burden.

Regulatory References

1. NIH MedlinePlus overview

Who can and cannot use Sinofin?

This section outlines the official eligibility and non-eligibility requirements as defined in governmental regulatory documents. The use of Sinofin is strictly limited to individuals who do not possess any of the documented conditions or history specified below.

---

Populations for whom use is Contraindicated

The medicine must not be used by patients who fall into the following categories, as defined by official labeling:

• Known Allergy: Individuals with a documented hypersensitivity or allergic reaction to the active substance (Sinofin) or to any of the inactive ingredients (excipients) in the product.
• Cross-Sensitivity: Patients with a history of asthma, urticaria (hives), or other allergic-type reactions following the use of aspirin or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs).

Eligibility-Related Restrictions

Official labeling defines specific clinical contexts where use is either prohibited or highly restricted:

• Post-Surgical Use: Sinofin is not recommended for use in the immediate setting of a specific major cardiac procedure, such as Coronary Artery Bypass Graft (CABG) surgery.

---

For all other adult populations without the above exclusions, use of Sinofin may be considered, provided no other limitations (e.g., pregnancy or specific organ impairment) are cited in the full prescribing information. Regulatory documents formally classify the allergy and cross-sensitivity exclusions as absolute Contraindications, meaning the risk outweighs any potential benefit in these specific populations.

Interactions with other medicines and products

The interaction profile for Sinofin (terbinafine) is primarily defined by pharmacokinetic alteration patterns documented in official regulatory labeling.

Classification	Description
Mechanistic Basis	Terbinafine is officially documented as an inhibitor of the Cytochrome P450 2D6 (CYP2D6) isozyme [Source 1.2, 1.4, 2.1].
Exposure-Increasing Agents	Co-administration with medicines like cimetidine and fluconazole is noted to significantly increase the plasma concentrations of terbinafine [Source 1.6, 2.1].
Exposure-Decreasing Agents	The medicine’s plasma exposure is documented to be reduced by co-administered enzyme inducers such as rifampin [Source 1.6, 2.1].

Officially Documented Interaction Statements

• Terbinafine affects the clearance of compounds predominantly metabolized by CYP2D6, which includes certain classes of medicines such as tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), and beta-blockers [Source 2.1].
• Terbinafine is documented to decrease the clearance of caffeine by 19% [Source 1.5, 2.2].
• Terbinafine is noted to increase the clearance of cyclosporine by 15% [Source 1.5, 2.2].
• The oral granule formulation of the medicine carries a specific timing constraint requiring administration with a soft, non-acidic food [Source 3.3].
• The medicine is not recommended for patients with chronic or active liver disease due to the potential for worse hepatic event outcomes [Source 1.6, 2.5].

Connection to the overall interaction profile

Regulatory documents define the product’s core interaction structure around its capability to inhibit the CYP2D6 enzyme, leading to potential changes in the systemic exposure of co-administered medicines that use this pathway [Source 2.1]. The clearance and plasma concentration of terbinafine itself are documented to be modified by co-administered CYP inducers and inhibitors [Source 2.1]. The official profile also includes non-drug constraints related to the administration of the oral granule formulation with food and a restriction related to pre-existing liver disease [Source 2.5, 3.3].

Fungal Enzyme Inhibition and Membrane Disruption

Sinofin's core action is the noncompetitive inhibition of the fungal enzyme squalene epoxidase. This targeted interaction halts the production of ergosterol, a vital component for the fungal cell membrane's structure. The resulting physiological effect is the rapid destabilization and increased permeability of the fungal cell membrane.

Metabolic Pathway Overload and Cell Death

The enzyme blockade causes the precursor molecule squalene to build up to toxic levels within the cell. This dual mechanism—membrane instability coupled with internal metabolic poisoning—initiates a cascade that leads directly to fungicidal cell lysis (killing the fungal cells). This action directly results in the clearance of the pathogen, which permits the body’s natural process of tissue replacement.

Selectivity and Physiological Constraints

The mechanism is selective because the drug targets a fungal enzyme distinct from its human cellular counterpart. However, the final physiological outcome—the physical replacement of damaged tissue—is constrained by the slow rate of natural tissue turnover in areas like the nails, which governs how quickly the physiological effect becomes fully visible.

The Official Administration Protocol

Sinofin is administered orally for systemic absorption, circulating throughout the body to reach deep-seated fungal infections. The medicine is primarily available as a 250 mg tablet or in a weight-based oral granule form for specific pediatric use.

The standard regimen for most adult patients is 250 mg once daily. The timing relative to meals depends on the formulation: the tablets may be taken with or without food, providing flexibility in the daily schedule. Conversely, the oral granules must be administered with a spoonful of soft, non-acidic food (such as pudding or mashed potatoes) and swallowed immediately without chewing; they must not be mixed with fruit-based foods.

---

Treatment Course and Duration

Treatment duration is determined by the specific anatomical site of the fungal infection:

Indication	Typical Duration
Fingernail Onychomycosis	6 weeks
Toenail Onychomycosis	12 weeks
Tinea Cruris or Corporis	2 to 4 weeks

---

Use Constraints and Scheduling

Specific constraints apply to use in certain patient populations. For example, use is not recommended in patients with pre-existing chronic or active liver disease, or in cases of severe renal impairment (creatinine clearance less than 50 mL/min).

To manage the scheduled once-daily dose, if a dose is missed, it should be taken as soon as possible. However, if the next scheduled dose is due within approximately four hours, the missed dose should be skipped entirely, and the normal schedule should be resumed. Double doses should not be taken.

Research Evidence / Overview of Studies for Sinofin

This section provides a transparent summary of the research conducted on oral terbinafine, the active ingredient in Sinofin, based on controlled clinical trials and scientific reviews. The information focuses only on what the research has explored and what the findings indicate, without offering any clinical advice or interpretation. Study results reflect the specific conditions under which they were conducted and do not determine whether an individual will respond similarly.

---

Evidence for Use in Fungal Nail Infections (Onychomycosis)

A substantial amount of research, including Randomized Controlled Trials (RCTs), was conducted on adults with confirmed dermatophyte fungal infections of the nails. These studies explored how two key measures changed over time: the mycological cure (fungal clearance confirmed by laboratory testing) and the clinical cure (the visual appearance of healthy, unaffected nail growth). Studies monitored these outcomes in comparison to placebo and other oral antifungals.

Research explored comparative rates of mycological cure, and some meta-analyses described patterns where the percentage of patients achieving cure was observed to be higher with terbinafine compared to intermittent itraconazole. Long-term prospective follow-up studies extending up to 5 years described patterns of recurrence. These studies observed that relapse rates in some patient groups were lower in those who received terbinafine when compared to those who received intermittent itraconazole.

---

Evidence for Use in Scalp Infections (Tinea Capitis)

Systemic therapy for Tinea capitis, a fungal infection predominantly affecting the scalp of children, was studied in comparative RCTs. These studies primarily included prepubescent children and monitored outcomes such as mycological cure and clinical cure (reduction in signs like scaling and hair loss).

Findings indicate a species-dependent pattern: for infections caused by the Trichophyton species, the evidence suggests that the findings reported high rates of mycological clearance. However, for infections caused by Microsporum species, systematic analyses reported that the rate of clearance was often lower in comparative studies examining terbinafine versus griseofulvin.

---

What is Still Uncertain in the Research Record

A key uncertainty is the variability in reported outcomes across studies, which may be linked to differences in the specific fungal organism or the study populations. Additionally, the risk of recurrence of certain infections, particularly tinea infections of the skin, appears to be a factor, with research describing patterns of clinical relapse in some settings. Limited information is available for long-term outcomes in patients with complex comorbidities like severe diabetes.

Key Studies & References

1. U.S. Food & Drug Administration - DailyMed: Terbinafine Labeling (Clinical Studies Section)
2. Oral treatments for toenail onychomycosis: a systematic review

Common questions about Sinofin (FAQ)

Q: Is Sinofin the same type of medicine as other drugs that treat the same condition?

A: Sinofin contains the active ingredient terbinafine. According to official product information, this medicine belongs to a specific pharmacological class known as allylamine antifungals.

---

Q: What is the difference between Sinofin and [Competitor Drug Name]?

A: Official research and drug overviews indicate that studies have explored comparisons between Sinofin's active ingredient and other oral antifungals. These studies monitor and describe patterns in mycological clearance rates and rates of recurrence in comparison to other medicines.

---

Q: Does Sinofin cause long-term side effects?

A: Official labeling emphasizes the need for regular monitoring of liver function tests and blood counts during therapy. Monitoring is required to observe for potential adverse changes related to the use of the medication, particularly in longer treatment courses.

---

Q: Can Sinofin be taken with over-the-counter pain relievers like ibuprofen?

A: The regulatory document's interaction profile focuses primarily on agents that modify certain liver enzymes (CYP2D6). No specific, consistent interaction with common over-the-counter pain relievers like ibuprofen is listed, but regulatory caution is generally advised regarding the simultaneous use of any medications.

---

Q: What happens if Sinofin is taken with alcohol?

A: While the drug's label does not always prohibit alcohol, official information frequently notes the importance of limiting or avoiding alcohol intake. This is primarily due to the medicine's known potential for hepatotoxicity (liver damage).

---

Q: Does taking Sinofin affect the results of any common blood tests?

A: The regulatory label requires periodic assessment of liver function tests to monitor for potential liver problems. Furthermore, official information mentions that rare cases of blood disorders have been reported, necessitating the monitoring of blood cell counts, which are used to detect these changes.

---

Q: Is it normal to feel a minor side effect when first starting Sinofin?

A: The most commonly reported adverse reactions, such as mild stomach upset or headache, are generally described in official sources as mild and transient. This suggests that effects may be experienced early on as the body adjusts to the medication.

---

Q: What is the typical timeframe for seeing the full benefit of Sinofin?

A: The full clearance of the infection and the appearance of healthy tissue are determined by the slow rate of natural tissue growth in the affected area, such as the nail bed. Therefore, the final clinical results may not be visible until several months after the fixed course of treatment has been completed.

---

Q: Is it true that Sinofin can cause drowsiness?

A: Official adverse reaction data includes occasional reports of dizziness and/or vertigo. Because of this, it is noted that caution should be exercised regarding activities such as driving or operating heavy machinery.

---

Q: Is Sinofin safe for older adults (seniors)?

A: Official dosing guidelines typically do not require a dose adjustment for older adults. However, use is subject to the general limitations for the drug, provided that the individual does not have specific health conditions, such as existing chronic liver or significant kidney impairment, as listed in the official contraindications.

---

Q: Has Sinofin been studied in children or adolescents?

A: Yes, the medication has officially been studied for the treatment of tinea capitis (scalp infection) in children. Dosing in this population is often based on the patient's body weight.

---

Q: Is there a generic version of Sinofin available?

A: Yes, the active ingredient in Sinofin, which is terbinafine, is widely available in generic formulations.

---

Q: Does Sinofin interact with birth control pills?

A: Official drug interaction statements include oral contraceptives (birth control pills). Official documents include this class of medicine, noting that the effectiveness of oral contraceptives may potentially be affected.

---

Q: Is Sinofin safe to use during pregnancy (as described in official sources)?

A: Official documents generally state that the drug is not recommended during pregnancy. This recommendation is based on the lack of adequate and controlled safety data from studies involving pregnant humans.

---

Q: Can Sinofin affect my ability to drive or operate machinery?

A: The official label suggests that caution should be observed if a patient experiences adverse effects such as dizziness or vertigo. These effects, if they occur, may potentially impair performance.

---

Q: Is there a risk of dependence or addiction with Sinofin?

A: No. The active ingredient in Sinofin, terbinafine, is not classified as a controlled substance by US federal regulatory agencies.

---

Q: Can Sinofin be split or crushed?

A: Official product information notes that the tablets are not scored and should generally not be altered. However, some authorized compounding references for patients unable to swallow pills describe methods for safely crushing and mixing the tablet with non-acidic foods or syrups.

---

Q: Is Sinofin intended to be a short-term or long-term treatment?

A: The medication is prescribed as a fixed-course treatment, with the duration (e.g., 6 or 12 weeks) determined by the specific site and type of fungal infection being treated. It is not intended for continuous, indefinite use.

---

Q: How often are the side effects of Sinofin reported?

A: Official documents categorize reported side effects by frequency. For example, some side effects are classified as Common (occurring in ge 1/100 to le 1/10 patients) or others are listed as Rare (occurring in ge 1/10,000 to le 1/1,000 patients).

---

Q: Does Sinofin interact with blood thinners like warfarin?

A: Official interaction statements specifically note that co-administration with blood thinners like warfarin may cause changes in blood clotting times (INR). Co-administration may require close monitoring of clotting times, as indicated in the regulatory information.

Storage Requirements

Official regulatory documents establish specific constraints to maintain the drug's stability. Sinofin must be stored below 30 C and should not be refrigerated or frozen unless the labeling directs otherwise. To protect the product from degradation due to environmental factors, it must be kept in its original package and the container should be tightly closed to shield it from moisture and light.

Disposal Instructions

For disposing of unused or expired medicine, the preferred method is to use a drug take-back program. If a take-back program is unavailable, the medicine should be mixed with an undesirable substance, such as dirt or used coffee grounds, placed in a sealed container, and discarded in the household trash. It is required to scratch out all personal information from the prescription label before disposal. The medicine should not be flushed down the toilet unless the official drug instructions specifically list it for that method.